Ultimovacs tests UV1 for ovarian cancer as part of triple combo therapy


Our investigative team came across this press release for a novel immunomodulation trial for ovarian cancer.  This trial will look at an aggressive combination of immunotherapy and PARP inhibitor olaparib.

Ultimovacs will test its experimental cancer vaccine UV1 as a triple-combination therapy for women with relapsed ovarian cancer who do not have mutations in their BRCA DNA repair genes. The Phase 2 DOVACC collaboration study is evaluating UV1 in combination with AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab) and PARP inhibitor Lynparza (olaparib) as maintenance therapy for women with high-grade ovarian cancer who respond to their second round of chemotherapy. The study is being carried out at over 30 clinical sites in 10 European countries.

Source link

Previous articleOvarian cysts: Common? Preventable?
Next articleThe Adelphi Breast Cancer Nutrition Seminar
“I help and guide women to defeat gynecologic cancers and advanced pelvic conditions such as endometriosis, using a unique combination of minimally invasive robotic surgery, precision medicine therapies and complementary holistic natural support towards thriving in survivorship." Dr. Vasilev is the only physician quadruple board certified in Ob-Gyn, Gynecologic Oncology and Integrative & Holistic Medicine in the United States. He is an accomplished advanced robotic surgeon and serves as Medical Director of Integrative Medicine and Integrative Gynecologic Oncology at Providence Saint John's Health Center, Professor at John Wayne Cancer Institute in Santa Monica, California and is Clinical Professor at Loma Linda University School of Medicine. He is former faculty and professor at UC Irvine, UCLA, USC and City of Hope. He is an active member of multiple medical societies and has been nationally listed in "Best Doctors" for 18 years.